Tolerability of β-Blocker Initiation and Titration in the Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF)

Patients with stable mild to moderate heart failure from the MERIT-HF trial, including subgroups of NYHA class II, III/IV, or III/IV with ejection fraction <0.25, heart rate ≤76 bpm, and systolic blood pressure ≤120 mm Hg.

Metoprolol CR/XL initiation and titration

Placebo

Combined end point of all-cause mortality or all-cause hospitalization during the first 90 dayscomposite